Biokine Therapeutics Announces Issuance of United States Patent

Biokine Therapeutics Announces Issuance of United States Patent covering the composition and use of novel chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation, and cancer (BKT130 project).

BioLineRx Receives Orphan Drug Designation for Novel Stem Cell Mobilization Treatment

BioLineRx Receives Orphan Drug Designation for Novel Stem Cell Mobilization Treatment BKT-140/BL-8040 previously received Orphan Drug Designation for treatment of Acute Myeloid Leukemia. BKT-140/BL-8040 is expected to commence Phase 1 trial in stem cell mobilization in Q2 2014, and top-line results are expected in H2 2014. Read More

BioLineRx Announces Regulatory Submission for Novel Stem Cell Mobilization Treatment

BioLineRx Announces Regulatory Submission for Novel Stem Cell Mobilization Treatment The phase 1 Trial of BKT-140/BL-8040 expected to begin in Q2 2014; top-line results expected in H2 2014 BKT-140/BL-8040 is also in Phase 2 for AML; top-line results expected in H2 2014 Read More

Go to Top